Indeed, the discovery of divergent pathological mechanisms between APOE4+ vs. APOE4− AD patients would not only point to important treatment differences for these two patient groups, but it could also help clarify the mechanism of AD pathogenesis in general. This evidence concerns the gene APOE and Alzheimer disease.